Disclaimer: All products are for laboratory research only and not for human or animal use or consumption. For in-vitro research by qualified professionals only
Disclaimer: All products are for laboratory research only and not for human or animal use or consumption. For in-vitro research by qualified professionals only
$60.00
21 in stock
Ships today if ordered and paid by 12 PM EST. (Except Saturdays & Sundays)
Due to our rigorous quality control standards and the fragile nature of our products, we cannot accept returns. In the rare occasion that your order arrives with missing, incorrect or damaged items, please email info@peptidessource.is for assistance. Our customer support representatives are standing by to ensure that our customers are 100% satisfied with our product quality, customer support and delivery. Cancellations must be requested by email before the order shipment has shipped. Once the order has shipped you may not cancel your order. Please contact us at info@peptidessource.is with any questions or concerns that you may have regarding your order. We will do our absolute best to assist you as quickly and satisfactorily as possible.Thank you.
$350.00
$260.00
$300.00
$220.00
$160.00
$160.00
$75.00
GLP-1 (SMA) is a GLP-1 receptor agonist peptide, and one of the most sought-after compounds in metabolic and incretin-pathway research. This listing supplies the 500mcg (25 tablets) oral tablets for laboratory research use. Every batch is tested to at least 98% purity by HPLC with a certificate of analysis (COA), is USA-made and third-party verified. For research use only; not for human or veterinary use or consumption.
GLP-1 (SMA) is a peptide agonist at the GLP-1 receptor. In preclinical systems researchers use it as a tool compound to study incretin-receptor signalling and how it compares with single-, dual- and triple-receptor research peptides. This describes a research mechanism only.
Incretin-receptor agonism has been examined in in-vitro receptor assays and animal metabolic-model research. GLP-1 (SMA) is used to probe receptor activity relative to other incretin research peptides. All referenced work is preclinical and mechanistic; no human data or outcomes are implied.
Typical applications include comparative receptor-signalling studies alongside GLP-2 (TRZ), GLP-3 (RTA) and Cagrilintide, plus metabolic-pathway model work. Browse the full metabolic & incretin research range for related material.
This is an oral tablet format and does not require reconstitution. Store the sealed tablets in a cool, dry place away from direct light and moisture; refrigeration is not required for the sealed product. Handle only in a controlled laboratory setting. For research use only, not for human or veterinary use or consumption.
GLP-1 (SMA) is a GLP-1 receptor agonist peptide. It is supplied strictly for laboratory research use as a tool compound in metabolic and incretin-pathway research.
In preclinical systems it acts as an agonist at the GLP-1 receptor, so researchers use it to study incretin-receptor signalling. This describes a research mechanism only, not an effect in humans.
This listing is the 500mcg (25 tablets) oral tablets. GLP-1 (SMA) is stocked in a range of strengths and formats, all linked in the specifications above.
No. This oral tablet format is supplied ready as-is and does not require reconstitution.
Keep the sealed tablets in a cool, dry place away from direct light, heat and moisture. Refrigeration is not required for the sealed oral product.
Each batch is tested to at least 98% purity by HPLC and ships with a certificate of analysis (COA). It is USA-made and independently third-party verified.
It is frequently studied alongside other incretin research peptides such as GLP-2 (TRZ) and GLP-3 (RTA), and amylin analogs such as Cagrilintide, in comparative receptor-signalling research.
No. It is sold strictly for laboratory and research use only, and is not for human or veterinary use, consumption, diagnosis or treatment.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, consumption, diagnosis or treatment. Statements describe a preclinical research context only and are not medical claims.
